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Topic 2 – Heart failure and cardiomyopathy
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Short and long term prognostic value of aortic pre ejection delay in
ischemic myocardiopathy
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Background: The assessment of the left ventricular systolic function is
usually based on the calculation of the ejection fraction by the echocardio-
graphy in the bi-dimensional mode. Some authors suggest that the simple
measurement of the echocardiographic indices (pre-ejection aortic time (PAT)
and aortic ejection time (AET), measured by pulsed Doppler), has a good cor-
relation with left ventricular ejection fraction (LVEF) in dilated cardiomyop-
athy. We propose to study the correlation of these parameters with LV
function in ischemic heart disease and especially its prognostic value.
Methods and results: This is a prospective study that includes 180
consecutive patients admitted for myocardial infarct with an EF <40% in sinus
rhythm and 20 control patients. The assessment of LVEF was performed by
transthoracic echocardiography, LV telediastolic volume, by the biplane Sim-
pson method, the lateral S-wave of the longitudinal LV function in tissue Dop-
pler, the TEI index of the aortic pre ejection time (APT) and aortic ejection
duration (AED) were performed by pulsed Doppler. The value of the APT is
inversely proportional to the LVEF, r=–0.6, P=0.002, and even the ratio APT
/ AED is inversely proportional to the LV EF with a good correlation (r=– 0.7,
p=0.001) and the longitudinal function (S’ wave) (r=–0.65, p=0.002) and pro-
portional for LV volume (for TDV, r=0.65, p=0.01). A ratio value of 0.35 pre-
dicts the LV EF to be <35% with a sensitivity of 90% and a specificity of
81%. The multivariate analysis reveals that this ratio is a predictor of hemo-
dynamic complications (44% vs. 23%, OR=2.1, p=0.01) and hospitalization
for sever heart failure episode at one year (21% vs. 12%, OR=1.9, p=0.001)
regardless of LV function, age and diabetes mellitus.
Conclusion: The aortic pre ejection time (APT), the aortic ejection dura-
tion (AED) and their ratio are simple parameters to measure and they can pre-
dict the impairment of the systolic function and have a short-term prognostic
value in the ischemic heart disease regardless of LV EF.
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Clinical evidence of LBBB-induced cardiomyopathy: reversal by
cardiac resynchronisation
Caroline Vaillant, Erwan Donal, Raphael Martins, Nathalie Behar, Christophe
Leclercq, Philippe Mabo, Jean Claude Daubert
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Purpose: Animal and clinical data have shown that left bundle branch
block (LBBB) induces mechanical dyssynchrony in the left heart. In heart
failure (HF) patients with low left ventricular (LV) ejection fraction, cardiac
resynchronisation therapy (CRT) is much more efficient when typical LBBB
is present. It has been postulated that lone LBBB could induce a progressive
decline in LV function via dyssynchrony leading to chronic HF with possible
recovery after CRT. However, the clinical evidence to support this hypothesis
is weak. The aim of this work was to study the prevalence and characteristics
of LBBB-induced cardiomyopathy cured by CRT.
Methods: All the patients referred to our center for CRT implantation from
2007 to 2011 (N=375) were investigated for LBBB history. Patients were
included if they presented an original syndrome consisting on:
– history of typical LBBB for ≥5 years,
– no evidence of structural heart disease at the time of LBBB diagnosis,
– progressive development of LV systolic dysfunction and HF symptoms
(NYHA class II-IV),
– presence of major mechanical dyssynchrony by cardiac imaging,
– absence of other etiology for cardiomyopathy,
– hyper-response to CRT as indicated by LVEF>45% after 1 year.
Results: 7 patients (2% of all screened pts) had the described syndrome.
The main patient characteristics and follow-up data are summarized in the fol-
lowing tables. Interestingly, two patients had HF symptoms and LV dysfunc-
tion recurrence after 3 and 6 years of CRT, respectively after withdraw of
CRT due to device removal in one (breast cancer) and battery depletion in the
other. After CRT resume, hyper-response was quickly re-observed in these
two cases.
Conclusion: These original data support the concept of LBBB-induced
cardiomyopathy with possible cure by CRT. The exact prevalence of the syn-
drome, the time needed to develop and predictive factors need to be assessed
in further prospective epidemiological studies.
Table – Main characteristics.
Table – Follow up data. 
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Hatem Bouraoui, Besma Trimeche, Ayoub Gherairi, Abdallah Mahdhaoui,
Samia Ernez, Gouider Jeridi
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Background: Heart failure (HF) and sleep apnoea (SA) association has
been recognized but whether it results from confounding factors (hyperten-
sion, ischaemia, obesity) remains unclear.
We aimed to determine the prevalence of SA in HF and to identify poten-
tial risk factors for SA in HF population.
Methods: We prospectively evaluated 70 patients with stable HF on opti-
mized therapy.
Polygraphy was performed. Type and severity of SA were defined
according international criteria. Demographic, anthropometric and clinical
characteristics were collected.
Results: SA was found in 73%, moderate to severe in a significant propor-
tion and predominantly central (63% of patients with SA). 
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Patient characteristics at time of LBBB diagnosis
Male 4
Age (years) 51 (36 to 60)
Chest pain as 1st symptom 2
Rate-dependent LBBB 3
QRS duration (msec) 136 (100 to 160)
Time to HF symptoms (years) 11,5 (5 to 21)
Time to CRT (years) 13,5 (16 to 22)
Pre- and post CRT Pre-implant 1 year
* YHA class I/II/III 0/3/4 5/2/0
* QRS duration (msec) 162 (150 to 180) 124 (110 to 135)
* T-pro BP (pg/ml) 2275±3200 159±11
* LVEF (%) 30 (20 to 39) 53 (45 to 62)
* LVEDD (mm) 63 (50 to 76) 50 (44 to 56)
* p<0,05
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Age>60 years (p<0.001), male (p<0.001), diabetes (68%) and hypertension
(59%) were associated with SA. Most patients with SA were sleepy (Epworth
>10).
Risk factors for central SA were age>60 years, male, sever heart failure:
III-IV NYHA; diastolic dysfunction whereas risk factors for obstructive SA
were age ≥60 years (p≤0.01), male (p≤0.001), BMI ≥30 Kg/m² (p≤0.001),
Epworth score >10 (p≤0.02) and diastolic dysfunction (p≤0.05).
Multivarious analysis showed only High body mass index is associated
with obstructive SA and NYHA III-IV and low left ejection fraction were in
central SA.
Conclusions: In our HF population, SA was prevalent, frequently asymp-
tomatic and without characteristic risk factors. Unlike previously reported,
central SA was the predominant type. These results suggest that SA is under
diagnosed in HF and there is a possible correlation between them, independent
of confounding factors. Recent advances in HF therapy might influence prev-
alence and type of SA in this population.
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Short- and long-term effects of nocturnal oxygen therapy on sleep
apnea in chronic heart failure
Philippe Bordier, Sébastien Orazio
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Background: To study short- and long-term effects of nocturnal oxygen
therapy (NOT) on sleep apnea (SA) in chronic heart failure (CHF).
Methods: In 51 consecutive stable CHF patients, NYHA II/III, left ventric-
ular ejection fraction (LVEF) ≤45%, baseline nocturnal ventilation polygraphy
identified 33 SA patients (apnea-hypopnea index (AHI) ≥15 events/h) who
were randomized to receive NOT 3 L/min (n=19) or no NOT (n=14). NOT
was applied for 6 months with a home concentrator, the first night with polyg-
raphy. Sixteen patients with NOT and 14 without NOT had polygraphy after
6 months.
Results: In patients without NOT, there was no significant difference
between baseline and the sixth month. In NOT patients, a marked AHI reduc-
tion was observed between baseline versus the first night and the sixth month,
respectively, 36.8±2.6 versus 20.8±3.0 and 18.3±2.4 events/h (p<0.0001) and
related to a central AHI decrease, respectively, 23.3±2.8 versus 8.3±1.6 and
6.1±1.4 events/h (p<0.0001). The oxygen desaturation index (ODI) evolved
similarly: 33.0±5.2 versus 7.5±0.5 and 9.3±2.6 events/h (p<0.0001). NOT had
no effects on obstructive and mixed AHI. In NOT patients versus those
without, respectively, AHI decreased by 49.0±6.0% versus increased by
2.0±14.0% (p<0.0001), ODI decreased by 59.0±9.4% versus 6.4±14.7%
(p=0.004), SaO2<90% time decreased by 61.4±9.9% versus increased by
60.0±68.4% (p=0.1) and LVEF increased by 14.5±10.2% versus 5.6±16.1%
(p=0.6). 
Conclusions: In stable CHF patients, NOT significantly reduced central
AHI and ODI, with acute effects being sustained over time and impacting nei-
ther obstructive and mixed AHI nor daytime LVEF.
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Background: After acute decompensated heart failure (ADHF), most
patients are often early discharged before treatment optimization. Following
months are important to optimize the treatment. We analyzed treatments at
discharge and at 3 months after discharge and the impact on outcome in
patients with heart failure and reduced left ventricular ejection fraction (HF-
REF).
Methods: French Society of Cardiology conducted a one-day national
survey in a randomized sample of 170 hospitals. All hospitalized patients with
a confirmed diagnosis of ADHF were included. Datas were recorded during
both hospitalizations and one-year follow up.
Results: Treatment informations at discharge as well as at 3 months were
obtained in 519 patients (age 72±14y, 34% females). At discharge, loop
diuretics were prescribed in 89% cases with daily dose of 87±146 mg, ACE-I
or ARB in 80% cases with daily dose reaching 36±31% of target dose, beta
blocker (BB) in 70% with daily dose of 27±51% of target dose, aldosterone
antagonists (AA) in 23% and digoxin in 9%. At 3 months, there was only few
changes in mean rates of prescriptions as compared to discharge (Table).
Clinical characteristics significantly associated with the lack of prescription at
3 months were creatininemia >15 mg/l for ACE-I/ARB, BB and AA, LVEF
>30% for BB and AA, and also COPD for BB.
All-cause-mortality at 12 months was 19% with marked differences
according to prescription or not of ACE-I/ARB at 3 months (15 vs 29%,
p=0.002) as well as BB (15 vs 27%, p=0.008). After adjustment on clinical
characteristics (age, blood pressure, creatininemia, LVEF, natriuretic peptides,
COPD, diabetes), lack of treatment at 3 months was an independant predictor
of mortality especially ACE-I or ARB (HR 2.50 [95%CI 1.33-4.73], p 0.005).
Conclusion: Individual treatments are poorly optimized after discharge.
Such inertia leads to poor outcome, that suggests a room to improve HF man-
agement in the practice, especially in the 3 months after discharge.
Table : Treatment changes
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Recipients and donors profile evolution in cardiac transplantation.
Single centre ten years experience.
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Objectives: We evaluated our 10-years experience in cardiac transplanta-
tion, taking into account the evolution of recipients and donors profiles.
Methods: Between January 2000 and December 2010, 664 patients under-
went isolated cardiac transplantation. Patients transplanted between 2000 and
2004 (Group I, n=243) have been compared to patients transplanted between
2005 and 2010 (Group II, n=421).
Results: The following characteristics were significantly different between
the two groups: among the recipients, age, 45 years (group I) vs. 48 years
(group II) p=0.01; high-emergency waiting list, 1% (group I) vs. 40% (group
II), p<0.01; days on waiting list, 162 (group I) vs. 119 (group II), p=0.01; dia-
betes, 10% (group I) vs. 16% (group II), p=0.02; preoperative mechanical cir-
culatory support with VAD, 20% (group I) vs. 8% (group II), p<0.01;
preoperative ECMO, 0% (group I) vs. 16% (group II), p<0.01 ; preoperative
Treatment’s 
changes 
after 
discharges
Stared Stopped Increased 
dose
Decreased 
dose
Median 
dose at 
discharge 
[IQR]
Median 
dose at 
3 months 
[IQR]
Loop 
diuretics
7% 6% 25% 29% 40 mg/day
[40-100]
40 mg/day
[20-80]
ACE-I or 
ARB
6% 10% 21% 35% 25 % of 
target dose
[25-50]
25 % of 
target dose
[0-50]
Betablockers 8% 9% 20% 31% 25 % of 
target dose
[12.5-50]
12.5 % of 
target dose
[0-50]
Aldosterone 
inhibitors
20% 6%
